The researchers discovered that inhibiting the NF-κB and Nrf2 pathways with the ERK1/2 inhibitor AZD0364 and the PI3K inhibitor ZSTK474 could reduce the expression of Nrf2 and ROS in ALL (REH, MOLT-4) and AML (MOLM-14) cell lines [193]. Here, NFE2L2 is linked to acute lymphoblastic leukemia.